Electra Therapeutics secures FDA ODD status for HLH treatment
The FDA’s ODD status is granted to investigational assets for treating diseases affecting less than 200,000 people in the US. This designation provides incentives such as tax credits for
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.
Denosumab has received approval in several countries and regions under different brand names for multiple indications, including osteoporosis treatment in postmenopausal women at high risk of fractures, among